Increased exposure & risk of hypotension w/ strong or moderate CYP3A4 inhibitors (PIs, azole antifungals, macrolides eg, erythromycin or clarithromycin, verapamil or diltiazem). Lower plasma conc w/ strong CYP3A4 inducers (eg, rifampicin,
Hypericum perforatum). Increased BP lowering effects w/ grapefruit or grapefruit juice & medicinal products w/ antihypertensive properties. Risk of hyperkalemia w/ dantrolene infusion. Increase tacrolimus blood levels. May increase exposure of mTOR inhibitors (eg, sirolimus, temsirolimus & everolimus). Increase trough conc of ciclosporin in renal transplant patients. Increased exposure w/ simvastatin.